Fosun Pharma | Briefing, News, Analysis, Research, Data

Fosun Pharma

Fosun Pharma is a pharmaceutical company.

Fosun Pharma, founded in May, 1995 and headquartered in Shanghai, is a pharmaceutical distribution, retail and medical service company. The founders are Chen Qiyu and Yao Fang. Listed on the HKEX on October 30, 2012, the company's major shareholders are Shanghai Fosun High Technology (Group) Co., Ltd., HKSCC Nominees Ltd and Hong Kong Securities Clearing Co., Ltd. Rivals that have direct and indirect competition with Fosun Pharma include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Specialty Pharma

Founded

May 31, 1995

HQ location

Shanghai, China

Legal name

Shanghai Fosun Pharmaceutical Co., Ltd.

Website

http://www.fosunpharma.com/

ir@fosunpharma.com

Employees

29656

All
News
Analysis
Research

Briefing May 31, 2022 05:58 PM · Technology | Real Estate | Industrials

Fosun Pharmaceutical: the new tablet production line of the holding subsidiary passed the GMP compliance inspection

Briefing May 25, 2022 05:30 PM · Technology | Industrials | Financials

Xuelang environment: affected by the epidemic situation, the subsidiary temporarily stopped production and resumed production

In-depth

Healthcare

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Aug 08, 2022 09:00 AM

Briefing May 20, 2022 05:04 PM · Industrials | Financials | Technology

Fosun Pharmaceutical: the holding subsidiary started the phase II clinical study on the treatment of fs-1502 for non-small cell lung cancer

Briefing May 11, 2022 05:17 PM · Technology | Financials | Healthcare

On May 11, Ping An of China spent 299 million yuan to buy back 6.6972 million a shares

Research

Healthcare

2022 China’s Healthcare Industry: An Introductory Handbook

Aug 29, 2022 05:45 PM

Research

Technology, Healthcare, Consumer Staples

WIA2020 | Rising Tech Stars 2020: Global & China's 100

Dec 09, 2020 09:57 AM

Research

Healthcare

WIA2020 | Next 50 in Global Tech: Healthcare

Dec 09, 2020 09:39 AM

Research

Healthcare, Real Estate, Industrials

Tech for Global, Globalization Footprints of the Established and the New

May 29, 2020 08:30 PM

Briefing Apr 26, 2022 05:15 PM · Technology | Financials | Healthcare

Sichuan Energy Investment Development: RMB 152 million subscription for Principal Guaranteed structured deposit products of Bank of Communications

Briefing Apr 25, 2022 09:55 AM · Consumer Discretionary | Healthcare

Jiangsu Province has issued the outline of building a strong province with intellectual property rights, and will be fully built into a strong province with intellectual property rights in 2035

Briefing Apr 19, 2022 01:35 PM · Technology | Industrials | Healthcare

Tesla unveiled a new giant 360mwh Megapack energy storage project

Briefing Feb 22, 2022 04:59 PM · Technology | Automotive | Healthcare

Chengda biology: transfer relevant assets of Benxi human vaccine base to a wholly-owned subsidiary

Financials, Healthcare

Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps

Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.

Apr 27, 2022 10:55 PM

Healthcare

Chinese Inactivated Vaccines against Omicron Variant Approved for Clinical Trial

Will the approval of the inactivated vaccines against Omicron variants help contain the spike in Covid-19 infections across China?

Apr 27, 2022 09:18 PM

Briefing Feb 17, 2022 10:08 AM

Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway

Briefing Feb 14, 2022 05:10 PM · Technology | Financials | Healthcare

Jiuyuan Yinhai: the holding subsidiary has passed the CMMI5 evaluation and certification

Briefing Feb 11, 2022 06:39 PM · Technology | Real Estate | Automotive

Shenghe resources: it plans to acquire 19.9% equity of peak company

In the COVID-19 vaccine development competition, every participant is speeding up. Image credit: Jeremy Lapak / Unsplash

Healthcare · Analysis

China Speed: Two COVID-19 Vaccines Recognized by WHO

As the second blow of the pandemic comes near the sight, China's newly-developed vaccines have been approved by the World Health Organization and available at an affordable price.

Oct 02, 2020 10:30 PM

Healthcare

Fosun Pharma’s COVID-19 Vaccine Starts Clinical Phase, Approved by Chinese NMPA

The giant Chinese pharmaceutical’s preventive vaccine is entering a new phase, bringing it closer to future commercialization.

Jul 14, 2020 10:40 AM

Briefing Jan 25, 2022 02:30 PM · Automotive | Healthcare

Japan launched measures to curb oil prices for the first time, with a subsidy of 3.4 yen per liter

Briefing Jan 24, 2022 06:29 PM · Real Estate | Healthcare

Rongchuang transferred the equity of Wenzhou No. 1 project company, and the transferee was Dexin real estate

Briefing Jan 24, 2022 02:39 PM

The main force continued to increase its position in lithium battery stocks in the late trading, and sold off banks and pharmaceutical stocks

Briefing Jan 18, 2022 04:49 PM · Financials | Automotive | Technology

Jianxin shares: the net profit in 2021 is expected to decrease by 71% - 80% year-on-year

EqualOcean Analysis